Investors Face August Deadline in ADMA Biologics Securities Fraud Suit
Investors in ADMA Biologics have until August 10, 2026, to seek appointment as lead plaintiff in a class action lawsuit filed in the U.S. District Court for the District of New Jersey. The litigation follows allegations that the biopharmaceutical company inflated its financial performance through deceptive sales practices.
The lawsuit, captioned Mazzarino v. ADMA Biologics, Inc., et al., accuses the company and its senior executives of violating federal securities laws by misrepresenting revenue growth. Plaintiffs allege that ADMA reported a 20% growth rate for 2025, which purportedly masked a 3% actual decline. The discrepancy allegedly stems from a channel stuffing scheme involving the company’s flagship liquid immune globulin product, ASCENIV. According to the complaint, ADMA induced distributors to stockpile excess inventory through aggressive rebates and extended payment terms to artificially meet sales targets.
The allegations surfaced following an investigative report by Culper Research on March 24, 2026, which detailed undisclosed related-party transactions. The disclosure triggered a sharp sell-off, with shares dropping 16.6% on the day of the report and an additional 15% the following session. Further downward pressure occurred on March 26, 2026, when Cantor downgraded the stock rating citing concerns over the research firm’s findings. Law firm Bleichmar Fonti & Auld LLP is representing investors in the action, which asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Shareholders affected by the price volatility are eligible to review their legal options through the firm.
Comments (0)
No comments yet. Be the first!